Opinion: STAT+: China’s strict new supply chain regulations could create massive problems for Western biopharma companies
China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.
ORIGINAL SOURCE →via STAT News Health
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · CN
- [HEALTH] Who writes the pandemic? State power, individual subjectivity, and the history of the present in China's COVID-19 respon
- [CONFLICT] UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
- [TECH] Nvidia açıkladı: Çin'de pazar payı sıfıra düştü
- [FINANCE] US sanctions China-based crude oil terminal operator for trading Iran oil
- [FINANCE] China tax compliance push tightens invoice quotas, slows copper cargo flow
- [CONFLICT] Two worlds collide: the regulatory battlefield hanging over the EU’s ties with China